physician, educator, student, researcher, veteran, and nature lover
Joined September 2013
- Tweets126
- Following329
- Followers134
- Likes819
Pinned Tweet
#vascularaccess is critical for the survival of patients with advanced #chronickidneydisease. Physicians should be mindful when ordering #PICCs for these patients. From @umichmedicine @UMich @HMS_MI @AnnalsofIM bit.ly/2Wmb0xD
David Paje retweeted
Elated to be presenting our MAGIC-ONC vascular access appropriateness recommendations in patients with cancer to the @HMS_MI consortium today!
Be sure to read the full paper published @AnnalsofIM: acpjournals.org/doi/10.7326/… #onctwitter
David Paje retweeted
Announcing the MAGIC-ONC guidelines for the placement and management of vascular access devices in patients with cancer, including specific recommendations for both hematologic and solid tumor malignancies. #MAGICOnc #onctwitter
acpjournals.org/doi/epdf/10.…
David Paje retweeted
Late night publication (finally!) of our MAGIC-ONC appropriateness guidelines for vascular access in patients with cancer. More to come tomorrow! #medtwitter #onctwitter acpjournals.org/doi/full/10.… – at Denver, CO
David Paje retweeted
Today, I am pleased to share the release of #MAGICOnc to the world.
acpjournals.org/doi/epdf/10.…
#MAGICOnc builds on the legacy of #MAGIC (acpjournals.org/doi/10.7326/…) in providing evidence-based guidance on what vascular device is most appropriate for patients with cancer.
David Paje retweeted
There's more in the full paper! Please take a look, share and most importantly IMPLEMENT and TEST in your patients with cancer.
Im grateful to @HMS_MI @PajeDavid @majorajay for leading this work. I truly hope it will bring better outcomes to patients!
David Paje retweeted
Deeply thankful to Dr. @vineet_chopra as well as Dr. @PajeDavid for their mentorship in bringing MAGIC-ONC to fruition!
We look forward to your feedback on these appropriateness guidelines, and encourage you to implement and test them in your patients with cancer. #onctwitter
Today, I am pleased to share the release of #MAGICOnc to the world.
acpjournals.org/doi/epdf/10.…
#MAGICOnc builds on the legacy of #MAGIC (acpjournals.org/doi/10.7326/…) in providing evidence-based guidance on what vascular device is most appropriate for patients with cancer.
David Paje retweeted
🚨 Just published: MAGIC-ONC — a new international framework to guide vascular access decisions in #cancer care. By treating VAD selection as a modifiable risk, we can improve outcomes & reduce harm.
acpjournals.org/doi/10.7326/… #MAGICONC #Oncology #VascularAccess #PatientSafety
David Paje retweeted
🚨 Are midline catheters a safe choice for vancomycin OPAT?
Despite guideline caution, evidence is limited. Using @HMS_MI data, we explored complication risks in hospitalized patients receiving OPAT—with & without vancomycin.
Clinical dogma, meet data. 💉📊 #PatientSafety #OPAT
Findings from @HMS_MI:
Administration of extended courses of vancomycin via midline catheters is associated with higher risks of serious complications and device failure.
This highlights importance of medication & vascular access device compatibility.
jamanetwork.com/journals/jam…
David Paje retweeted
🌼 HMS is celebrating Nurses Week by honoring those who champion quality and safety behind the scenes. Your dedication ensures that every patient receives the highest quality of care possible. 🩺
Thank you for your unwavering commitment to excellence! 🙏
#NursesWeek25
Always a pleasure to share what we learn from @HMS_MI!
Grateful for the opportunity to meet with and be inspired by the high-performing and impressive team at @CUDivHospMed!
#highqualityvascularaccess
David Paje retweeted
📊💡 New evidence shows how hospitalist Medical Procedure Services (MPS) improve outcomes! MPS cuts length of stay, enables weekend procedures, & boosts same-day discharges. #PatientCare
🔗: doi.org/10.1002/jhm.13484
✍️:@PajeDavid, @StephptaylorCLT, @curtisy_call
David Paje retweeted
Midline catheters used for outpatient parenteral antimicrobial therapy (OPAT) had a lower risk of major complications compared to PICCs, especially for treatments lasting 14 days or fewer.
ja.ma/3Z1NCEC
David Paje retweeted
‼️ New findings from #HMS suggest that midline catheters are safe alternatives to PICCs for OPAT, especially for treatment durations of 14 or fewer days.
Read the @JAMAInternalMed publication here 👉jamanetwork.com/journals/jam…
David Paje retweeted
New paper hot off the press from @JAMAInternalMed. Congrats to @PajeDavid for leading this effort!
What's better for #OPAT? Midlines or PICCs? And what duration is best for both devices?
jamanetwork.com/journals/jam…
David Paje retweeted
On 11/21/24, @MiAVANetwork is hosting its fall conference and vendor fair in Ann Arbor. Use the QR code to register and listen to five excellent speakers discuss vascular access. #HMS #PICC Physician lead Dr. @PajeDavid will share our journey in improving PICC/midline practice.
David Paje retweeted
Improving mobility for hospitalized patients is a high-priority research area for U-M hospital medicine!
Congrats to HM research project manager and @umichDLHS MEL-STAR scholar @TrevDenton on presenting his important LHS work on digital innovation for getting patients to move!
David Paje retweeted
Great presentation this morning at AVA 2024 on the importance of vein preservation in patients with renal failure/impairment. Always nice to see our HMS data shared at National Conferences!
David Paje retweeted
HMS Rockstars @vineet_chopra @PajeDavid @engineertodoc presenting at AVA 2024 on our Midline Initiative! It is such a privilege to help inform best practices and national standards for vascular device use.
